Featured Education

Bridging the Gap to Reach Treatment Goals in DLBCL

Click here to learn more

The Evolution of HCT

Click here to learn more

Improving Survival in First-Line Metastatic NSCLC with Dual Checkpoint Blockade: Exploring Recent Data and Treatment Strategies / Activity 1

Click here to learn more

Improving Survival in First-Line Metastatic NSCLC with Dual Checkpoint Blockade: Real-world Applications in Clinical Practice / Activity 2

Click here to learn more

Creating Patient-centered Approaches to Optimal Care: Best Practices for Utilizing BCMA-directed Therapy

Click here to learn more

Navigating the Evidence: Pathways for New and Emerging BCMA Therapies

Click here to learn more

On Demand Activities

More results...

Therapeutics Areas
Learner Specialties
Expires After
  • On-Demand
Episode 3 of 3 - Help Your Patients Navigate Risk-benefit Assessment, Choose the Best Therapy for Them, and Mitigate TEAEs
  • Credit: 0.30hr(s)
  • AAPA, CME, CPE, NCPD
  • December 1, 2022 — 
  • December 14, 2023
  • Therapeutic Areas: Hematologic Oncology, Oncology
  • Specialties: Chronic Lymphocytic Leukemia (CLL), Small lymphocytic lymphoma (SLL)
  • Location: Internet Activity Enduring
In the advent of novel targeted therapies for the treatment of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), clinicians must consider the potential of adverse events (AEs) that can affect patient outcomes. In the last episode of the 3-part educational series First-line Treatment of CLL/SLL: New Data and Practical Strategies for Practice Improvement, our expert faculty will engage in an interactive discussion on AE-management to promote optimal treatment-decision making for clinicians. In addition, learn tips to on how to counsel your patients on monitoring their symptoms to support timely and effective care.
Enroll Today
View Course
  • On-Demand
Transitioning from Chemoimmunotherapy to More Targeted Approaches in MCL
  • Credit: 1.0hr(s)
  • CME, CPE, MOC, NCPD
  • October 14, 2022 — 
  • October 30, 2023
  • Therapeutic Areas: Hematologic Oncology, Hematology, Oncology, Pathology
  • Specialties: Lymphoma, Mantle Cell Lymphoma
  • Location: Internet Activity Enduring
The natural history of mantle cell lymphoma (MCL) is a repeated pattern of remission and relapse; after a few relapses, patients have a very small chance of responding to any therapy. Considerable progress has been made over the last decade as the treatment paradigm has shifted from traditional chemoimmunotherapy toward targeted and cell-based therapies in both the frontline and relapsed/refractory (R/R) settings. However, selecting the best treatment is often complicated, involving multiple patient factors, and there is no established standard of care. During Transitioning from Chemoimmunotherapy to More Targeted Approaches in MCL, experts discuss using prognostic tools to plan treatment for individuals with MCL and targetable mutations, integrating emerging data and guidelines recommendations for front-line treatment, potential benefits and risks of chemotherapy-free targeted options, planning safe and effective use of novel therapies and combinations in the second- and third-line settings and for R/R MCL, and eradicating health inequities and closing the survival gap. This taped Satellite Symposium was derived from the Society of Hematologic Oncology 2022 Annual Meeting.
Enroll Today
View Course
  • On-Demand
GVHD-E3 | ECHO Program: Sclerotic Chronic GVHD
  • Credit: 1.0hr(s)
  • CME, NCPD
  • September 26, 2022 — 
  • September 26, 2023
  • Therapeutic Areas: Family Medicine / Primary Care, General Medicine
  • Specialties: Primary Care
  • Location: Internet Activity Enduring
The goal of the GVHD Interactive Provider Network ECHO Program is to connect GVHD specialists with community providers to share expertise, discuss cases and improve patient care.     The network is based on the ECHO Model™ (Extension for Community Healthcare Outcomes) which uses proven adult learning techniques and interactive video technology to connect community providers with specialists in collaborative sessions. The sessions, designed around case-based learning and mentorship, will help primary care and community-based practitioners gain the practical expertise required to care for GVHD patients.
Enroll Today
View Course
  • On-Demand
Improving Survival in First-Line Metastatic NSCLC with Dual Checkpoint Blockade: Real-world Applications in Clinical Practice / Activity 2
  • Credit: 0.50hr(s)
  • AAPA, CME, CPE, NCPD
  • February 17, 2023 — 
  • February 16, 2024
  • Therapeutic Areas: Hematologic Oncology, Oncology
  • Specialties: NSCLC, Oncology
  • Location: Internet Activity Enduring
This educational initiative is designed for community-based oncology clinicians (physicians, nurse practitioners [NPs], physician assistants [PAs], pharmacists, and nurses) to enhance outcomes for individuals with who provide care for individuals with mNSCLC. This interactive online activity uses the game-based platform Kahoot! to test participant ability to identify and apply key learning points to metastatic NSCLC (mNSCLC) patient cases while competing against their colleagues. Expert faculty will discuss the emerging efficacy and safety data for CTLA-4 inhibitor combination regimens in mNSCLC and explore strategies to identify patients who would most benefit from these therapies through the use of biomarkers. Additionally, there will be an in-depth discussion regarding approaches to effectively collaborate with other clinicians and mNSCLC patients to provide cost-effective, equitable, and inclusive care for patients of all socioeconomic and racial/ethnic backgrounds. Join us for Part 1 of this question and answer based educational activity, Improving Survival in First-line Metastatic NSCLC with Dual Checkpoint Blockade: Exploring Recent Data and Treatment Strategies for an in-depth dive into the data!
Enroll Today
View Course
  • On-Demand
Episode 1 of 3 - What You MUST Know About the Emerging Standard of Care for 1L Treatment of CLL and SLL
  • Credit: 0.30hr(s)
  • AAPA, CME, CPE, NCPD
  • December 1, 2023 — 
  • December 14, 2023
  • Therapeutic Areas: Hematologic Oncology, Oncology
  • Specialties: Chronic Lymphocytic Leukemia (CLL), Small lymphocytic lymphoma (SLL)
  • Location: Internet Activity Enduring
The treatment landscape in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) has shifted with the advent of novel targeted agents that are more tolerable than traditional chemoimmunotherapy. However, keeping up with the latest clinical evidence and updates to the clinical guidelines on these agents can be challenging for busy clinicians and their care teams. In this first episode of the 3-part educational series First-line Treatment of CLL/SLL: New Data and Practical Strategies for Practice Improvement, sit in on a conversation with our expert faculty as they discuss the new standard of care for CLL and SLL and how to apply this care transition to your patients and clinic.
Enroll Today
View Course
  • On-Demand
Mastering MRD for Prognosis and Treatment in ALL
  • Credit: 1.0hr(s)
  • CME, CPE, MOC, NCPD
  • October 14, 2022 — 
  • October 29, 2023
  • Therapeutic Areas: Hematologic Oncology, Hematology, Oncology, Pathology
  • Specialties: Acute Lymphocytic Leukemia (ALL), Leukemia, Minimal Residual Disease
  • Location: Internet Activity Enduring
Acute lymphoblastic leukemia (ALL) is the first hematologic neoplasm for which assessment of early response to therapy using measurable residual disease (MRD) has proven to be a fundamental tool for guiding therapy. It should be a key component in individualizing care to improve outcomes for patients. But MRD is a time point-dependent variable, with different time points signifying different prognosis for relapse. And MRD testing methods are variable across clinical practices, and it can be challenging to select the appropriate combination and sequence of therapy. Consequently, not all patients are provided with uniform care. During Mastering MRD for Prognosis and Treatment in ALL, experts will discuss conducting MRD testing for patients with ALL according to the guideline-recommended schedule; evaluating the specimens needed for, and the pros and cons of, various methods for assessing MRD; predicting the risk of relapse based on MRD test results; and individualizing treatment based on MRD status to ensure patients at higher risk of relapse receive appropriate risk-adapted therapy. This taped Satellite Symposium was derived from the Society of Hematologic Oncology 2022 Annual Meeting.
Enroll Today
View Course
View All MLI Activities
Facebook Twitter Linkedin Instagram
Subscribe to Mailing List